Eric Dobmeier - Jul 19, 2024 Form 4/A Insider Report for Janux Therapeutics, Inc. (JANX)

Role
Director
Signature
/s/ James Pennington, Attorney-in-Fact
Stock symbol
JANX
Transactions as of
Jul 19, 2024
Transactions value $
$0
Form type
4/A
Date filed
7/24/2024, 08:00 PM
Date Of Original Report
Jul 22, 2024
Previous filing
Jun 27, 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JANX Common Stock Award $0 +1.23K +24.62% $0.00 6.23K Jul 19, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JANX Stock Option (Right to Buy) Award $0 +4.11K $0.00 4.11K Jul 19, 2024 Common Stock 4.11K $44.68 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the grant of RSUs, each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on July 19, 2025, subject to the Reporting Person's continuous service on such date.
F2 The shares subject to the option will vest in twelve equal monthly installments over one year, subject to the Reporting Person's continuous service on each such date.

Remarks:

This amendment is being filed to correct the number of RSUs and the number of shares subject to the option.